Adlai Nortye (ANL) Receivables - Other (2023 - 2025)

Adlai Nortye's (ANL) quarterly Receivables - Other came in at $907000.0 in Q4 2025, up 262.8% year-on-year from $250000.0 in Q4 2024, and up 292.64% on a QoQ basis from $231000.0 in Q2 2025.

Adlai Nortye (ANL) Receivables - Other (2023 - 2025) Analysis & Trends

Adlai Nortye (ANL) has 3 years of Receivables - Other data on file, last reported at $907000.0 in Q4 2025.

  • On a quarterly basis, Receivables - Other rose 262.8% year-over-year to $907000.0 in Q4 2025; TTM through Dec 2025 was $907000.0, a 262.8% increase from a year earlier, with the FY2025 full-year figure at $907000.0, up 262.8% from the prior year.
  • Receivables - Other for Q4 2025 stood at $907000.0, up from $231000.0 in the prior quarter.
  • Over the last five years, Receivables - Other for ANL reached as high as $907000.0 in Q4 2025 and fell as low as $224000.0 in Q4 2023.
  • Historically, Receivables - Other has averaged $403000.0 across 3 years, with a median of $240500.0 in 2024.
  • Across the five-year window, Receivables - Other rose 11.61% in 2024 and soared 262.8% in 2025, its largest moves.
  • Year by year, Receivables - Other stood at $224000.0 in 2023, then gained by 11.61% to $250000.0 in 2024, then surged by 262.8% to $907000.0 in 2025.
  • Per Business Quant data, the three most recent Receivables - Other figures were $907000.0 in Q4 2025, $231000.0 in Q2 2025, and $250000.0 in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 66,621.14 Bn 66,620.85 Bn -
2 Nanobiotix 1,915.18 Bn 1,915.11 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.27 Bn 466.48 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.81 Bn 114.57 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 69.58 Bn 60.82 Bn 3.31 Bn
7 Belite Bio 62.72 Bn 62.72 Bn -
8 Argenx Se 55.51 Bn 50.33 Bn 1.41 Bn
9 Revolution Medicines 37.35 Bn 37.35 Bn -
10 Adlai Nortye 1.16 Bn 1.15 Bn -

Historic Data

Download Data
DateValue
Dec 31, 2025 907,000.00
Dec 31, 2025 907,000.00
Jun 30, 2025 231,000.00
Jun 30, 2025 231,000.00
Dec 31, 2024 250,000.00
Dec 31, 2024 250,000.00
Dec 31, 2023 224,000.00
Dec 31, 2023 224,000.00